Search Videos by Topic or Participant
Browse by Series:

Introduction: Neoadjuvant Chemotherapy in Bladder Cancer

Insights From: Dean F. Bajorin, MD, MSKCC; Daniel P. Petrylak, MD, Yale;Evan Y. Yu, MD, Seattle Cancer Care  
Published: Friday, Mar 27, 2015
For High-Definition, Click
Muscle-invasive bladder cancer presents as a systemic disease in a substantial number of patients, with neoadjuvant chemotherapy representing an optimal standard of care. However, despite this, many community practices do not commonly administer neoadjuvant chemotherapy, Dean F. Bajorin, MD, notes. 

Neoadjuvant chemotherapy should be administered followed by consolidation surgery, such as cystectomy and bilateral pelvic lymph node dissection, for patients with muscle-invasive bladder cancer, believes Bajorin. Two of the leading neoadjuvant chemotherapy regimens are cisplatin, methotrexate, and vinblastine (CMV) and methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC). Adverse events associated with these therapies include renal toxicity, myelosuppression, mucositis, and infection. 

At this time, neoadjuvant chemotherapy should be utilized for all patients with muscle-invasive bladder cancer. Evidence has suggested that ERCC2 mutations could correlate with sensitivity to cisplatin-based regimens; however, Bajorin comments that clinical trials exploring both ERCC1 and ERCC2 as predictive markers of chemotherapy in bladder cancer have not shown conclusive results.
Slider Left
Slider Right
For High-Definition, Click
Muscle-invasive bladder cancer presents as a systemic disease in a substantial number of patients, with neoadjuvant chemotherapy representing an optimal standard of care. However, despite this, many community practices do not commonly administer neoadjuvant chemotherapy, Dean F. Bajorin, MD, notes. 

Neoadjuvant chemotherapy should be administered followed by consolidation surgery, such as cystectomy and bilateral pelvic lymph node dissection, for patients with muscle-invasive bladder cancer, believes Bajorin. Two of the leading neoadjuvant chemotherapy regimens are cisplatin, methotrexate, and vinblastine (CMV) and methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC). Adverse events associated with these therapies include renal toxicity, myelosuppression, mucositis, and infection. 

At this time, neoadjuvant chemotherapy should be utilized for all patients with muscle-invasive bladder cancer. Evidence has suggested that ERCC2 mutations could correlate with sensitivity to cisplatin-based regimens; however, Bajorin comments that clinical trials exploring both ERCC1 and ERCC2 as predictive markers of chemotherapy in bladder cancer have not shown conclusive results.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x